Olmibite Beta 50 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 50 mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and reduced aldosterone secretion, thereby lowering blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac efficiency. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing for enhanced patient compliance. Olmibite Beta 50 is indicated for the management of hypertension, either as monotherapy or in patients requiring combination therapy to achieve target blood pressure levels. It may also be beneficial in patients with coexisting conditions such as ischemic heart disease or heart failure, where beta-blockade is advantageous. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Olmibite Beta 50 should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.